Company intelligence

RIGL

Rigel Pharmaceuticals, Inc. · NASDAQ · Healthcare

Price$39.65-13.26% · −$6.06

Market cap740.66MEquity value

P / E10.1Trailing ratio

Volume758.98KLatest session

Market data

RIGL price chart

TradingView

Related signals

1 min delayed

Browse public RIGL signals with their source context and measured market impact. Open any signal for its permanent analysis page.

RIGLOct 30, 2025+0.89% since signal

This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is 'growing substantially'

RIGL's stock soared 50% in the last three months. CEO highlighted consistent growth and profitability in recent interview. Second-quarter earnings surpassed analyst expectations significantly. Full-year revenue guidance was raised to $270-$280 million. Clinical trials for new drugs R835 and Ocadusertib are underway.

View signal analysis

RIGLJul 24, 20240.00% since signal

Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential

RIGL's portfolio includes FDA-approved therapies Tavalisse, Rezlidhia, and Gavreto. Analysts consider RIGL undervalued with a strong potential for revenue growth. Gavreto's sales could significantly increase RIGL's revenue over the next years. R289 shows potential for treating MDS, suggesting a promising pipeline. RIGL is categorized as a strong buy, but relies on successful commercialization.

View signal analysis

Research